Historic Press Releases
Achilles Therapeutics plc
Achilles Therapeutics Holdings Limited
Achilles Therapeutics UK Limited
(“The Companies”)
Ian Harvey Dean and Robert Scott Fishman (“the Liquidators”) were appointed Joint Liquidators of the Companies further to resolutions of the respective member of the Companies dated 20 March 2025.
All licensed Insolvency Practitioners of Teneo Financial Advisory Limited (“Teneo”) are licensed in the UK to act as Insolvency Practitioners by the Institute of Chartered Accountants in England and Wales.
Historic Press Releases
The documents listed below were issued by the Companies prior to the Liquidations commencing. The Liquidators accept no responsibility or liability in respect of these documents.
Date
Title
Apr 4 2024
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
Feb 28 2025
Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration
Dec 24 2024
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
Nov 19 2024
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Nov 14 2024
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
Sep 19 2024
Achilles Therapeutics Announces Strategic Update
Aug 14 2024
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
May 22 2024
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 17 2024
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
May 8 2024
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Apr 4 2024
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Feb 5 2024
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Dec 18 2023
Achilles Therapeutics Announces Publication of Nature Cancer 'Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction
Nov 13 2023
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
Sep 22 2023
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Aug 4 2023
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Jun 12 2023
Achilles Therapeutics to Present at Upcoming Conferences
May 10 2023
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 10 2023
Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
Apr 25 2023
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
Apr 25 2023
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Apr 17 2023
Achilles Therapeutics to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Mar 7 2023
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
Dec 20 2022
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 6 2022
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
Nov 30 2022
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
Nov 22 2022
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
Nov 8 2022
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Oct 6 2022
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
Aug 9 2022
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Jul 21 2022
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
Jun 30 2022
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board
Jun 21 2022
Achilles Therapeutics Recognized with the 2022 PING Innovation Award
May 10 2022
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 9 2022
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
May 4 2022
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
May 3 2022
Achilles Therapeutics to Present at Upcoming Conferences
Apr 12 2022
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
Apr 5 2022
Achilles Therapeutics to Present at Upcoming Conferences
Apr 4 2022
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
Mar 8 2022
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
Mar 1 2022
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights
Feb 7 2022
Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.
Jan 13 2022
Achilles Therapeutics Provides Business Update and Outlook for 2022
Dec 21 2021
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 20 2021
Achilles Therapeutics Added to the NASDAQ Biotechnology Index
Dec 9 2021
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
Nov 12 2021
Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing
Nov 9 2021
Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights
Oct 22 2021
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor Types
Oct 12 2021
Achilles Therapeutics to Join the Northern Alliance Advanced Therapy Treatment Centre Consortium
Oct 1 2021
Achilles Therapeutics to Present at Upcoming Scientific Congresses
Sep 2 2021
Achilles Therapeutics to Present at Upcoming Investor Conferences
Aug 25 2021
Achilles Therapeutics Announces Grant of US and European Patents
Aug 10 2021
Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
Jul 1 2021
Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer
Jun 4 2021
Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 11 2021
Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 6 2021
Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
May 5 2021
Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference
May 3 2021
Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board
Apr 10 2021
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Apr 6 2021
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
Mar 30 2021
Achilles Therapeutics Announces Pricing of Initial Public Offering
Mar 10 2021
Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021
Mar 1 2021
Achilles Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States
Feb 5 2021
Achilles Therapeutics Announces Additional Financing Plans
Feb 5 2021
Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials
Feb 4 2021
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
Jan 7 2021
Achilles Therapeutics to present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 7 2020
Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications
Dec 1 2020
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer
Nov 19 2020
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours
Nov 17 2020
Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer
Oct 7 2020
Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer
Oct 7 2020
Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer
Jun 23 2020
Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer
May 29 2020
Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens
May 28 2020
Achilles Therapeutics to present at Jefferies Virtual Healthcare Conference
May 13 2020
Achilles Therapeutics announces formation of Scientific Advisory Board
Apr 22 2020
Achilles Therapeutics to present a manufacturing update at the virtual 2020 AACR Annual Meeting
Apr 7 2020
Achilles Therapeutics appoints Carsten Boess to the Board of Directors
Mar 17 2020
Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer
Jan 7 2020
Achilles Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Nov 28 2019
Achilles Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
Nov 14 2019
Achilles Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
Oct 21 2019
Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer - Brings 20+ years of business development experience - Formerly VP, Business Development for the Immuno-inflammation Therapy Area at GSK
Sep 3 2019
ACHILLES THERAPEUTICS RAISES £100 MILLION IN OVERSUBSCRIBED SERIES B FINANCING
Feb 13 2019
ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN METASTIC OR RECURRENT MELANOMA - Second CTA approval in 2019 - the first was for a NSCLC study
Jan 21 2019
ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER - Ground-breaking clinical trial in patients with significant unmet medical need to start this year
Dec 10 2018
ACHILLES THERAPEUTICS APPOINTS DR EDWIN MOSES AS CHAIRMAN OF ITS BOARD OF DIRECTORS AND DR IRAJ ALI AS CHIEF EXECUTIVE OFFICER
Sep 19 2018
ACHILLES TODAY ANNOUNCES THAT IT HAS APPOINTED SENIOR PHARMACEUTICAL EXECUTIVE MICHAEL F. GIORDANO, M.D., TO ITS BOARD OF DIRECTORS.
Apr 26 2017
ACHILLES' FOUNDERS MAP TRUNCAL AND BRANCHED MUTATIONS AND COPY NUMBER EVENTS TO PREDICT EARLY RELAPSE IN NON-SMALL CELL LUNG CANCER.
Jan 3 2017
ACHILLES STARTS 2017 WITH MOVE TO STEVENAGE BIOSCIENCE CATALYST
Sep 28 2016
ACHILLES LAUNCHES WITH FUNDS OF £13.2M TO DEVELOP IMMUNOTHERAPIES FOR CANCER